Leprosy

What is Leprosy?

Leprosy, also known as Hansen disease, is a chronic infectious disease caused by the bacteria Mycobacterium leprae. This ancient disease primarily affects the skin, peripheral nerves, and mucous membranes, causing characteristic hypopigmented (light-colored) patches with loss of sensation, nerve thickening, and potential deformity if untreated. While historically feared and stigmatized, leprosy is now completely curable with multidrug therapy (MDT) and has a very low transmission rate. The disease remains endemic in parts of Asia, Africa, and South America, affecting approximately 200,000 new people annually worldwide.

Key statistics

Symptoms

Early symptoms include hypopigmented skin patches with loss of sensation, numbness in hands and feet, muscle weakness, and thickened peripheral nerves.

Leprosy symptoms develop slowly over years and vary depending on the form of disease. The earliest signs are usually pale or reddish skin patches that have lost sensation to touch, heat, or pain. These patches may be flat or slightly raised and can appear anywhere on the body. As the disease progresses, affected nerves become visibly thickened, particularly those close to the skin surface such as the ulnar nerve at the elbow or the greater auricular nerve in the neck.

Numbness and tingling in the hands and feet are common early symptoms, often starting in the fingers and toes before spreading. Muscle weakness develops as motor nerves become damaged, leading to characteristic deformities such as claw-like hands, foot drop, or facial paralysis. Eye involvement can cause dryness, reduced blinking, and potential vision problems. In more severe forms, nasal congestion, nosebleeds, and collapse of the nasal bridge may occur. Skin lesions can become nodular and widespread in untreated cases.

Submit Your Paper

Causes and risk factors

Leprosy is caused by infection with Mycobacterium leprae, a slow-growing bacteria related to the organism that causes tuberculosis. The exact mode of transmission remains unclear, but it likely spreads through respiratory droplets from prolonged close contact with untreated patients. Importantly, 95% of the global population has natural immunity to leprosy.

Risk factors include prolonged close contact with an untreated patient, living in endemic areas, poverty and poor living conditions, malnutrition, and certain genetic factors that may affect immune response. Age is also a factor, with most cases occurring in adults aged 20-40, though children can be affected. Contrary to historical beliefs, leprosy is not highly contagious and casual contact does not lead to transmission.

Prevention

Prevention of leprosy relies primarily on early detection and treatment of cases to interrupt transmission. In endemic areas, contact screening of household members and close contacts of patients is recommended. The BCG vaccine, primarily used for tuberculosis prevention, may provide some protection against leprosy, particularly the more severe forms.

There is no specific leprosy vaccine currently available for routine use. Post-exposure prophylaxis with single-dose rifampin may be considered for close contacts in some situations. Public health measures focus on improving living conditions, nutrition, and access to healthcare in endemic areas. Education programs help reduce stigma and encourage early treatment seeking.

Complications

Without treatment, leprosy can cause permanent nerve damage leading to severe disability and deformity. Sensory loss in hands and feet increases the risk of unnoticed injuries, burns, and infections that can result in tissue damage and loss of digits. Motor nerve damage causes muscle weakness and characteristic deformities including claw hands, wrist drop, foot drop, and facial paralysis.

Eye complications can lead to blindness if untreated. Nasal cartilage destruction may cause collapse of the nasal bridge and breathing difficulties. Secondary bacterial infections of skin lesions and wounds are common. Social stigma and discrimination, though medically unjustified, can lead to profound psychological impact and social isolation. Early treatment prevents virtually all of these complications.

Diagnosis

Leprosy diagnosis is primarily clinical, based on the presence of characteristic skin lesions with loss of sensation, thickened peripheral nerves, and positive skin smears in some cases. The World Health Organization criteria include hypopigmented or reddish skin patches with definite loss of sensation, thickened or enlarged peripheral nerves, and positive skin smears for acid-fast bacilli.

Skin biopsy may be performed for histopathological examination to confirm diagnosis and classify the type of leprosy. Nerve conduction studies can assess the extent of nerve damage. The lepromin skin test, while not diagnostic, helps classify the disease type. Polymerase chain reaction (PCR) testing can detect M. leprae DNA but is not routinely available in all settings. Differential diagnosis includes other skin conditions such as vitiligo, tinea versicolor, and other mycobacterial infections.

Treatment

Leprosy is completely curable with multidrug therapy (MDT), provided free of charge by the World Health Organization. The standard treatment regimen includes dapsone, rifampin, and clofazimine. For multibacillary (MB) leprosy, treatment duration is 12 months, while paucibacillary (PB) leprosy requires 6 months of treatment.

The three-drug combination prevents the development of drug resistance and ensures cure. Patients become non-infectious within days of starting treatment. Additional medications may include corticosteroids to manage inflammatory reactions (reversal reactions or erythema nodosum leprosum). Surgical interventions may be necessary to correct deformities or restore function, including tendon transfers, nerve decompression, or reconstructive procedures. Physical therapy and rehabilitation help maintain function and prevent disability.

Prognosis

With early diagnosis and appropriate treatment, the prognosis for leprosy is excellent. Multidrug therapy provides a 100% cure rate, and patients can expect a normal lifespan. Treatment halts disease progression and prevents further nerve damage, though existing nerve damage may be permanent.

Early treatment, ideally before nerve damage occurs, allows for complete recovery without disability. Even in cases with some nerve damage, proper treatment prevents further progression and many complications can be managed effectively. The main prognostic factors are early diagnosis and treatment compliance. Untreated leprosy can lead to severe disability and deformity, but these outcomes are entirely preventable with timely intervention.

Quality of life

People successfully treated for leprosy can lead completely normal lives. There are no dietary restrictions or lifestyle limitations once treatment is completed. Regular exercise is encouraged to maintain joint mobility and muscle strength, particularly important for those with some residual nerve damage.

Mental health support may be beneficial given the historical stigma associated with leprosy. Many patients benefit from counseling and support groups to address anxiety, depression, or social challenges. Occupational therapy can help adapt daily activities for those with hand or foot weakness. Protective footwear and careful attention to skin care are important for those with residual sensory loss. Return to work and normal social activities is expected and encouraged.

Pregnancy and fertility

Leprosy does not affect fertility in men or women. Pregnancy is safe for women with leprosy, and the disease does not typically worsen during pregnancy. Multidrug therapy can be continued safely during pregnancy and breastfeeding, as the benefits of treatment far outweigh any potential risks.

Pregnant women with leprosy should receive standard MDT under medical supervision. The infection is rarely transmitted from mother to baby, and breastfeeding is safe and encouraged. Babies born to mothers with leprosy should be monitored but can receive routine vaccinations. Genetic counseling is not necessary as leprosy is an infectious disease, not an inherited condition.

Children

Children can develop leprosy, particularly in endemic areas or if exposed to untreated cases in the household. Pediatric leprosy often presents differently than adult disease, with fewer skin lesions and more involvement of facial nerves. The incubation period may be shorter in children.

Treatment regimens are modified based on body weight, and children respond very well to therapy. School attendance should continue during treatment as children become non-infectious rapidly. Family education is important to ensure treatment compliance and reduce stigma. Contact screening of other family members is essential when a child is diagnosed.

When to see a doctor

Seek medical attention promptly if you develop skin patches that have lost sensation to touch, heat, or cold, particularly if you live in or have traveled to an endemic area. Other warning signs include persistent numbness or tingling in hands or feet, unexplained muscle weakness, or visible thickening of peripheral nerves.

Urgent evaluation is needed if you develop sudden onset of severe nerve pain, new muscle weakness, or eye problems such as inability to close eyelids completely. Anyone with a household contact diagnosed with leprosy should be screened by a healthcare provider. Early diagnosis and treatment prevent disability and complications.

Regional context

Leprosy cases in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean are rare, with most countries having achieved elimination as a public health problem. Sporadic cases may occur in travelers returning from endemic areas or in migrant populations.

Healthcare providers in these regions should maintain awareness of leprosy signs and symptoms, particularly when evaluating patients with relevant travel or contact history. We invite contributions from regional medical professionals to share local epidemiological data and clinical experiences with Global Medical Journal.

Research and clinical trials

Current research focuses on developing shorter treatment regimens, improved diagnostics, and potential vaccines. Studies are investigating single-dose treatments and combination therapies that could reduce treatment duration. Research into rapid diagnostic tests, including point-of-care testing, aims to improve early detection.

Vaccine development includes research into new M. leprae vaccines and optimization of BCG vaccination schedules. Genetic studies are exploring host susceptibility factors and drug resistance mechanisms. Clinical trials can be found on ClinicalTrials.gov, though active leprosy treatment trials are limited due to the effectiveness of current MDT regimens. Much current research focuses on prevention strategies and managing treatment complications.

Frequently asked questions

Is leprosy highly contagious?

No, leprosy has very low transmission rates. About 95% of people are naturally immune, and patients become non-infectious within days of starting treatment.

Can leprosy be completely cured?

Yes, leprosy is 100% curable with multidrug therapy. Early treatment prevents disability and allows for complete recovery.

Does leprosy cause body parts to fall off?

No, this is a myth. Leprosy causes nerve damage that leads to loss of sensation, making injuries more likely, but it does not cause body parts to “fall off.”

Can I get leprosy from touching someone who has it?

Casual contact does not transmit leprosy. Prolonged close contact with an untreated patient may rarely lead to transmission, but most people are naturally immune.

Is leprosy still a problem today?

While greatly reduced, leprosy still affects about 200,000 people annually worldwide, primarily in parts of Asia, Africa, and South America. It remains a concern in endemic areas.

Support and resources

• World Health Organization (WHO) Global Leprosy Programme: www.who.int/health-topics/leprosy
• International Federation of Anti-Leprosy Associations (ILEP): www.ilepfederation.org
• American Leprosy Missions: www.leprosy.org
• DAHW German Leprosy and Tuberculosis Relief Association: www.dahw.org
• Sasakawa Health Foundation: www.shf.or.jp/en

Related conditions

Tuberculosis, Peripheral neuropathy, Vitiligo, Cutaneous leishmaniasis, Mycobacterium ulcerans infection

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.